What treatment options are available for JAK2-positive essential thrombocythemia?
For JAK2-positive essential thrombocythemia, treatment depends on your symptoms and risk factors. Risk is assessed based on platelet counts, age (especially if 60 or older), history of blood clots or bleeding, smoking, high blood pressure Show Full Answer
What treatment options are available for JAK2-positive essential thrombocythemia?
For JAK2-positive essential thrombocythemia, treatment depends on your symptoms and risk factors. Risk is assessed based on platelet counts, age (especially if 60 or older), history of blood clots or bleeding, smoking, high blood pressure, and the presence of JAK2 mutation.
If you're at low risk without symptoms, your doctor may recommend a "watch and wait" approach with regular monitoring and blood tests.
When treatment is needed, common options include:
• Low-dose aspirin to reduce blood clot risk and symptoms like headaches
• Hydroxyurea (chemotherapy) to reduce platelet production in high-risk patients
• Agrylin (anagrelide) to lower platelet counts
• Interferon alfa for specific cases, particularly women of childbearing age
JAK2 inhibitors like ruxolitinib (Jakafi) are being studied for essential thrombocythemia treatment, though they're currently approved for other MPNs.
The main goal is preventing blood clots and bleeding complications. Your treatment plan should be personalized based on your individual risk factors and how your disease is progressing.
October 28, 2025
Join
Your Privacy Choices
